fg-4592 and Nephritis

fg-4592 has been researched along with Nephritis* in 1 studies

Other Studies

1 other study(ies) available for fg-4592 and Nephritis

Article	Year
Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury. Clinical science (London, England : 1979), 2018, 04-16, Volume: 132, Issue:7 Renal hypoxia occurs in acute kidney injury (AKI) of various etiologies. Activation of hypoxia-inducible transcription factor (HIF) has been identified as an important mechanism of cellular adaptation to low oxygen. Preconditional HIF activation protects against AKI, suggesting a new approach in AKI treatment. HIF is degraded under normoxic conditions mediated by oxygen-dependent hydroxylation of specific prolyl residues of the regulative α-subunits by HIF prolyl hydroxylases (PHD). FG-4592 is a novel, orally active, small-molecule HIF PHD inhibitor for the treatment of anemia in patients with chronic kidney disease (CKD). The current study aimed to evaluate the effect of FG-4592 (Roxadustat) on Topics: Acute Kidney Injury; Animals; Antineoplastic Agents; Apoptosis; Cisplatin; Drug Evaluation, Preclinical; Glycine; Hypoxia-Inducible Factor-Proline Dioxygenases; Isoquinolines; Male; Mice, Inbred C57BL; Nephritis	2018

Article

Year

Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury.

Clinical science (London, England : 1979), 2018, 04-16, Volume: 132, Issue:7

Renal hypoxia occurs in acute kidney injury (AKI) of various etiologies. Activation of hypoxia-inducible transcription factor (HIF) has been identified as an important mechanism of cellular adaptation to low oxygen. Preconditional HIF activation protects against AKI, suggesting a new approach in AKI treatment. HIF is degraded under normoxic conditions mediated by oxygen-dependent hydroxylation of specific prolyl residues of the regulative α-subunits by HIF prolyl hydroxylases (PHD). FG-4592 is a novel, orally active, small-molecule HIF PHD inhibitor for the treatment of anemia in patients with chronic kidney disease (CKD). The current study aimed to evaluate the effect of FG-4592 (Roxadustat) on

Topics: Acute Kidney Injury; Animals; Antineoplastic Agents; Apoptosis; Cisplatin; Drug Evaluation, Preclinical; Glycine; Hypoxia-Inducible Factor-Proline Dioxygenases; Isoquinolines; Male; Mice, Inbred C57BL; Nephritis

2018